<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934191</url>
  </required_header>
  <id_info>
    <org_study_id>15-011707</org_study_id>
    <nct_id>NCT02934191</nct_id>
  </id_info>
  <brief_title>Celecoxib After Tonsillectomy</brief_title>
  <official_title>Celecoxib for Pain Management After Tonsillectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tonsillectomy is one of the most common pediatric surgical procedures in the United States.
      Postoperative pain is substantial, with typical regimens employing narcotic derivatives and
      acetaminophen for 1-2 weeks after surgery. Recent enthusiasm for use of ibuprofen as an
      alternative has been tempered by equivocal data on its relative safety in regard to risk of
      postoperative hemorrhage. The primary objective is to evaluate efficacy of celecoxib for pain
      control after tonsillectomy in children. The secondary objective is to assess safety in
      regard to postoperative hemorrhage and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial. Subjects will take
      acetaminophen plus either celecoxib or placebo in regular scheduled doses, and will
      supplement as needed with standard of care analgesic therapy (oxycodone/acetaminophen).

      Celecoxib is approved by the FDA for use in children ages 2 and older for treatment of
      juvenile rheumatoid arthritis (JRA). Celecoxib is on the Children's Hospital of Philadelphia
      (CHOP) formulary for use in (1) patients &gt;= 2 years old for JRA, (2) patients &gt;= 12 years old
      and &gt;=40 kg who have increased risk for gastrointestinal (GI) adverse effects or bleeding
      concerns precluding use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs), and (3)
      oncology patients with surface area &gt;= 0.4 square meters for anti-angiogenesis. Celecoxib is
      approved by the FDA for use in adults for treatment of arthritic conditions, acute/
      postoperative pain, and primary dysmenorrhea, and has been widely used since its introduction
      in 1998.

      Setting/Participants:Subjects are healthy children aged 3 to 11 years who undergo
      tonsillectomy with or without adenoidectomy at any Children's Hospital of Philadelphia (CHOP)
      location. Subjects with coagulation disorders are excluded. Approximately 300 subjects will
      be enrolled, 150 in each treatment group.

      Study Interventions and Measures: Subjects are provided celecoxib or placebo in scheduled
      doses every 12 hours for 5 days, then continue until they are pain-free, for a maximum of 10
      days. Throughout the study, they are allowed to use oxycodone/acetaminophen as needed for
      additional pain control, following standard clinical care. Acetaminophen is used around the
      clock for the first 5 days in all subjects. For 14 days following surgery, subjects record
      pain levels on validated pain scale instruments, quantity of narcotic medication and
      acetaminophen required, and time to return to normal diet. All Emergency Department and
      hospital admissions during the 30 postoperative days are recorded, noting incidence of excess
      pain, dehydration, hemorrhage, and other complications.

      Pain control efficacy is assessed by comparing groups for number of days in which narcotic
      medication was used, and total quantity of rescue pain medication consumed. Rates of hospital
      readmission and postoperative hemorrhage, and the need for operative control, are also
      compared between groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Number of Days Requiring Rescue Pain Medication</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>The number of days on narcotic pain medication following surgery will be compared between the two treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Amount of Rescue Pain Medication Consumed</measure>
    <time_frame>2 weeks post-operative</time_frame>
    <description>The total amount of rescue pain medication consumed in the 2-week postop period will be compared between the two treatment groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Tonsillectomy</condition>
  <arm_group>
    <arm_group_label>Acetaminophen/Oxycodone + Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen/Oxycodone + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally</description>
    <arm_group_label>Acetaminophen/Oxycodone + Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
    <arm_group_label>Acetaminophen/Oxycodone + Placebo</arm_group_label>
    <other_name>Calcium carbonate placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.</description>
    <arm_group_label>Acetaminophen/Oxycodone + Celecoxib</arm_group_label>
    <arm_group_label>Acetaminophen/Oxycodone + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.</description>
    <arm_group_label>Acetaminophen/Oxycodone + Celecoxib</arm_group_label>
    <arm_group_label>Acetaminophen/Oxycodone + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 3 to 11 years inclusive.

          2. Scheduled to undergo tonsillectomy (with or without adenoidectomy).

          3. Weight ≥10 kg.

          4. Girls ≥ 11 years of age must have a negative urine/serum pregnancy test on the day of
             surgery and must use an acceptable method of contraception, including abstinence, a
             barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the
             duration of the study.

          5. Parental/guardian permission (informed consent) and if appropriate, child assent.

        Exclusion Criteria:

          1. Prior adenotonsillar surgery.

          2. Concomitant surgical procedure that adds more than mild additional pain. Note: ear
             tubes are always permissible.

          3. Coagulation disorder, or any other hematologic disorder that affects clotting or
             results in anemia.

          4. Moderate to severe asthma, defined as subjects who either (1) have daily symptoms
             requiring daily use of short-acting bronchodilators, or (2) had an exacerbation in the
             last 3 months requiring admission, emergency department (ED) visit, or systemic
             corticosteroid administration.

          5. Any degree of aspirin-sensitive asthma, or any history of asthma exacerbation caused
             by NSAID use.

          6. Severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index &gt;30 per
             hour and/or lowest oxygen saturation below 80%

          7. Significant chronic pulmonary disease, defined as subjects requiring oxygen therapy,
             ventilator support, or positive pressure therapy.

          8. Significant cardiac disease, defined as any one of the following: cardiovascular
             disease, structural cardiac anomalies, prior cardiac surgery, or requirement for
             cardiac anesthesia.

          9. Severely obese (weight or body mass index &gt; 95th percentile for age) or underweight
             (weight &lt;5th percentile for age).

         10. History of hepatic or renal disease, or condition that impairs hepatic or renal
             function.

         11. Juvenile rheumatoid arthritis (JRA).

         12. History of GI bleeding, or chronic GI condition that would increase risk of bleeding,
             ulceration, or perforation

         13. Hypertension.

         14. Craniofacial syndromes.

         15. Syndrome or neurologic condition that would hinder accurate assessment of
             postoperative pain.

         16. Inability to feed orally or take oral pain medication.

         17. Chronic pain disorders, or otherwise requiring pain medication more than once weekly.

         18. Laboratory abnormalities on the preoperative complete blood count (CBC):

               -  Hemoglobin &lt; 9 gm/dL

               -  Platelet count &lt; 100,000/mm3

         19. Any investigational drug use within 30 days prior to enrollment.

         20. Pregnant or lactating females.

         21. Parents/guardians or subjects who, in the opinion of the Investigator, may be
             non-compliant with study schedules or procedures.

         22. Hypersensitivity or allergic reactions to celecoxib, aspirin, or other NSAIDs,
             including asthma flare ups

         23. Allergy to sulfonamides or calcium carbonate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Germiller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2019</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tonsillectomy</keyword>
  <keyword>Post-operative complications</keyword>
  <keyword>Post-operative pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02934191/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen/Oxycodone + Celecoxib</title>
          <description>Subjects will take acetaminophen orally in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Celecoxib: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally.</description>
        </group>
        <group group_id="P2">
          <title>Acetaminophen/Oxycodone + Placebo</title>
          <description>Subjects will take acetaminophen orally in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Placebo: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen/Oxycodone + Celecoxib</title>
          <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Celecoxib: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen/Oxycodone + Placebo</title>
          <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Placebo: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.27" lower_limit="4.74" upper_limit="7.75"/>
                    <measurement group_id="B2" value="5.72" lower_limit="4.44" upper_limit="6.96"/>
                    <measurement group_id="B3" value="6.03" lower_limit="4.48" upper_limit="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Number of Days Requiring Rescue Pain Medication</title>
        <description>The number of days on narcotic pain medication following surgery will be compared between the two treatment groups</description>
        <time_frame>2 weeks post-operative</time_frame>
        <population>Subjects with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen/Oxycodone + Celecoxib</title>
            <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Celecoxib: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen/Oxycodone + Placebo</title>
            <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Placebo: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of Days Requiring Rescue Pain Medication</title>
          <description>The number of days on narcotic pain medication following surgery will be compared between the two treatment groups</description>
          <population>Subjects with evaluable data</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="3.35"/>
                    <measurement group_id="O2" value="5.75" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Amount of Rescue Pain Medication Consumed</title>
        <description>The total amount of rescue pain medication consumed in the 2-week postop period will be compared between the two treatment groups.</description>
        <time_frame>2 weeks post-operative</time_frame>
        <population>Subjects with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen/Oxycodone + Celecoxib</title>
            <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Celecoxib: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen/Oxycodone + Placebo</title>
            <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Placebo: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Amount of Rescue Pain Medication Consumed</title>
          <description>The total amount of rescue pain medication consumed in the 2-week postop period will be compared between the two treatment groups.</description>
          <population>Subjects with evaluable data</population>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="1.12"/>
                    <measurement group_id="O2" value="1.40" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Adverse events were collected for the 30 day postoperative period, and were collected systematically from the day 3, day 14, day 30 telephone calls, and the Study Diary</desc>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen/Oxycodone + Celecoxib</title>
          <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Celecoxib: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen/Oxycodone + Placebo</title>
          <description>Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
Placebo: Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Gastroenteritis with admission</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Dehydration resulting in admission</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental infection</sub_title>
                <description>Dental infection with facial swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Surgical site hemorrhage</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea / Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="87"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="87"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Germiller</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>215-590-3440</phone>
      <email>germiller@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

